Clinical experience with Adalimumab in a multicenter Swiss cohort of patients with Crohn's disease

Background: Controlled clinical trials have demonstrated the efficacy and safety of adalimumab in patients with moderate-to-severe Crohn’s disease (CD), but there is, however, only